147 related articles for article (PubMed ID: 16996111)
41. Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer.
Ninomiya T; Yamagami W; Susumu N; Makabe T; Sakai K; Wada M; Takigawa A; Chiyoda T; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
Anticancer Res; 2016 Apr; 36(4):1751-8. PubMed ID: 27069155
[TBL] [Abstract][Full Text] [Related]
42. Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study.
Mäenpää J; Leminen A
Cancer Chemother Pharmacol; 2009 Jul; 64(2):297-300. PubMed ID: 19020876
[TBL] [Abstract][Full Text] [Related]
43. Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer.
Obata H; Aoki Y; Watanabe M; Matsushita H; Yahata T; Fujita K; Kurata H; Tanaka K
Int J Clin Oncol; 2003 Feb; 8(1):53-5. PubMed ID: 12601544
[TBL] [Abstract][Full Text] [Related]
44. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study.
Fushida S; Kinoshita J; Yagi Y; Funaki H; Kinami S; Ninomiya I; Fujimura T; Nishimura G; Kayahara M; Ohta T
Oncol Rep; 2008 May; 19(5):1305-10. PubMed ID: 18425392
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
Covens AL; Filiaci V; Gersell D; Lutman CV; Bonebrake A; Lee YC
Gynecol Oncol; 2011 Feb; 120(2):185-8. PubMed ID: 21075433
[TBL] [Abstract][Full Text] [Related]
46. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Oza AM; Eisenhauer EA; Elit L; Cutz JC; Sakurada A; Tsao MS; Hoskins PJ; Biagi J; Ghatage P; Mazurka J; Provencher D; Dore N; Dancey J; Fyles A
J Clin Oncol; 2008 Sep; 26(26):4319-25. PubMed ID: 18591547
[TBL] [Abstract][Full Text] [Related]
47. A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study.
Maisano R; Mare M; Caristi N; Chiofalo G; Picciotto M; Carboni R; Mafodda A; La Torre F
J Chemother; 2005 Apr; 17(2):242-6. PubMed ID: 15920913
[TBL] [Abstract][Full Text] [Related]
48. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
Goodwin RA; Jamal R; Tu D; Walsh W; Dancey J; Oza AM; Elit L; Eisenhauer EA
Gynecol Oncol; 2013 Nov; 131(2):315-20. PubMed ID: 23938374
[TBL] [Abstract][Full Text] [Related]
49. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
van Wijk FH; Lhommé C; Bolis G; Scotto di Palumbo V; Tumolo S; Nooij M; de Oliveira CF; Vermorken JB;
Eur J Cancer; 2003 Jan; 39(1):78-85. PubMed ID: 12504662
[TBL] [Abstract][Full Text] [Related]
50. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.
Muggia FM; Blessing JA; Sorosky J; Reid GC
J Clin Oncol; 2002 May; 20(9):2360-4. PubMed ID: 11981008
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
Tsoref D; Welch S; Lau S; Biagi J; Tonkin K; Martin LA; Ellard S; Ghatage P; Elit L; Mackay HJ; Allo G; Tsao MS; Kamel-Reid S; Eisenhauer EA; Oza AM
Gynecol Oncol; 2014 Nov; 135(2):184-9. PubMed ID: 25173583
[TBL] [Abstract][Full Text] [Related]
52. The feasibility study of docetaxel in patients with anaplastic thyroid cancer.
Kawada K; Kitagawa K; Kamei S; Inada M; Mitsuma A; Sawaki M; Kikumori T; Fujimoto Y; Arima H; Imai T; Ando Y
Jpn J Clin Oncol; 2010 Jun; 40(6):596-9. PubMed ID: 20200039
[TBL] [Abstract][Full Text] [Related]
53. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
Castonguay V; Lheureux S; Welch S; Mackay HJ; Hirte H; Fleming G; Morgan R; Wang L; Blattler C; Ivy PS; Oza AM
Gynecol Oncol; 2014 Aug; 134(2):274-80. PubMed ID: 24882554
[TBL] [Abstract][Full Text] [Related]
54. Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer.
Warm M; Nawroth F; Ohlinger R; Valter M; Pantke E; Mallmann P; Harbeck N; Kates R; Thomas A
Onkologie; 2007 Sep; 30(8-9):436-41. PubMed ID: 17848815
[TBL] [Abstract][Full Text] [Related]
55. Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer.
Karasawa K; Katsui K; Seki K; Kohno M; Hanyu N; Nasu S; Muramatsu H; Maebayashi K; Mitsuhashi N; Haga S; Kimura T; Takahashi I
Breast Cancer; 2003; 10(3):268-74. PubMed ID: 12955041
[TBL] [Abstract][Full Text] [Related]
56. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.
McMeekin DS; Lisyanskaya A; Crispens M; Oza AM; Braly P; Doering D; Bayever E; Michiels B; Markman M
Gynecol Oncol; 2009 Aug; 114(2):288-92. PubMed ID: 19476988
[TBL] [Abstract][Full Text] [Related]
57. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.
Kunos CA; Sill MW; Buekers TE; Walker JL; Schilder JM; Yamada SD; Waggoner SE; Mohiuddin M; Fracasso PM
Gynecol Oncol; 2011 Feb; 120(2):224-8. PubMed ID: 21075438
[TBL] [Abstract][Full Text] [Related]
58. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study.
D'hondt R; Paridaens R; Wildiers H; Pauwelyn K; Thomas J; Dumez H; Van Oosterom AT
Anticancer Drugs; 2004 Apr; 15(4):341-6. PubMed ID: 15057137
[TBL] [Abstract][Full Text] [Related]
59. Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study.
Seeholzer N; Thürlimann B; Köberle D; Hess D; Korte W
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):415-23. PubMed ID: 17581315
[TBL] [Abstract][Full Text] [Related]
60. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Matulonis U; Vergote I; Backes F; Martin LP; McMeekin S; Birrer M; Campana F; Xu Y; Egile C; Ghamande S
Gynecol Oncol; 2015 Feb; 136(2):246-53. PubMed ID: 25528496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
